Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Weighted Average and Diluted) (2019 - 2025)

Historic EPS (Weighted Average and Diluted) for Cartesian Therapeutics (RNAC) over the last 7 years, with Q3 2025 value amounting to -$1.38.

  • Cartesian Therapeutics' EPS (Weighted Average and Diluted) fell 2212.39% to -$1.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.44, marking a year-over-year increase of 9726.5%. This contributed to the annual value of -$4.46 for FY2024, which is 9103.61% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported EPS (Weighted Average and Diluted) of -$1.38 as of Q3 2025, which was down 2212.39% from $0.5 recorded in Q2 2025.
  • Cartesian Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.54 during Q2 2024, with a 5-year trough of -$41.56 in Q4 2023.
  • Over the past 5 years, Cartesian Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.22 (recorded in 2021), while the average stood at -$3.37.
  • Per our database at Business Quant, Cartesian Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 304359.51% in 2022 and then crashed by 10297731.86% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at $0.12 in 2021, then tumbled by 66.34% to $0.04 in 2022, then crashed by 102977.32% to -$41.56 in 2023, then soared by 96.63% to -$1.4 in 2024, then increased by 1.33% to -$1.38 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$1.38 in Q3 2025, compared to $0.5 in Q2 2025 and -$0.68 in Q1 2025.